“…In agreement with previously published data, our study showed a high prevalence of BRAF mutations in melanoma (44%) and, to much lesser extent, in thyroid, colorectal, and ovarian cancer (8%, 6%, and 5%, respectively). In regard to individual aberrations, oncogenic mutations in two hot-spot regions (exons 9 and 20) of PIK3CA have been identified in various malignancies, including common tumors such as breast, lung, colorectal, ovarian and uterine (Table 3) [6,11]. In this study, PIK3CA mutations were identified in 11% of diverse tumor types.…”